Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MediciNova has received a notice of allowance for a Japanese patent covering the use of ibudilast (MN-166) for the treatment of multiple forms of chronic neuropathic pain.
Subscribe to our email newsletter
MN-166 is used for certain neurological conditions, including progressive forms of multiple sclerosis, neuropathic pain, and drug addiction.
The patent once received is expected to expire by the end of 2025 and covers a method of treating certain existing chronic neuropathic pain conditions by administering ibudilast either alone or in combination with other active ingredients.
MediciNova president and chief executive officer Yuichi Iwaki said the company is encouraged with the continuing expansion of use and composition exclusivity around its ibudilast and related analog program.